Church T, Margolis S
Front Cell Dev Biol. 2025; 12:1531797.
PMID: 39990094
PMC: 11842346.
DOI: 10.3389/fcell.2024.1531797.
Witkowska J, Gizynska M, Karpowicz P, Sowik D, Trepczyk K, Hennenberg F
ACS Chem Biol. 2025; 20(2):266-280.
PMID: 39907714
PMC: 11851449.
DOI: 10.1021/acschembio.4c00341.
Sedlacek J
ACS Pharmacol Transl Sci. 2025; 8(1):21-35.
PMID: 39816802
PMC: 11729432.
DOI: 10.1021/acsptsci.4c00408.
Li F, Liu J, Fu Y
Curr Treat Options Oncol. 2024; 25(11):1354-1365.
PMID: 39432172
DOI: 10.1007/s11864-024-01273-6.
Loy C, Trader D
Molecules. 2024; 29(14).
PMID: 39064934
PMC: 11279888.
DOI: 10.3390/molecules29143356.
Visualizing chaperone-mediated multistep assembly of the human 20S proteasome.
Adolf F, Du J, Goodall E, Walsh Jr R, Rawson S, von Gronau S
Nat Struct Mol Biol. 2024; 31(8):1176-1188.
PMID: 38600324
PMC: 11327110.
DOI: 10.1038/s41594-024-01268-9.
Visualizing chaperone-mediated multistep assembly of the human 20S proteasome.
Adolf F, Du J, Goodall E, Walsh Jr R, Rawson S, von Gronau S
bioRxiv. 2024; .
PMID: 38328185
PMC: 10849659.
DOI: 10.1101/2024.01.27.577538.
Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome.
Fernandes P, Guedes R, Victor B, Salvador J, Guedes R
Front Chem. 2024; 11:1322628.
PMID: 38260042
PMC: 10801056.
DOI: 10.3389/fchem.2023.1322628.
Acceleration of Protein Degradation by 20S Proteasome-Binding Peptides Generated by In Vitro Artificial Evolution.
Zhu Y, Shigeyoshi K, Hayakawa Y, Fujiwara S, Kishida M, Ohki H
Int J Mol Sci. 2023; 24(24).
PMID: 38139315
PMC: 10743564.
DOI: 10.3390/ijms242417486.
Mass Spectrometric Profiling of HLA-B44 Peptidomes Provides Evidence for Tapasin-Mediated Tryptophan Editing.
Kaur A, Surnilla A, Zaitouna A, Mumphrey M, Basrur V, Grigorova I
J Immunol. 2023; 211(9):1298-1307.
PMID: 37737643
PMC: 10592002.
DOI: 10.4049/jimmunol.2300232.
New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies.
Guedes R, Grilo J, Carvalho A, Fernandes P, Ressurreicao A, Brito V
Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37631011
PMC: 10458307.
DOI: 10.3390/ph16081096.
Minimal mechanistic component of HbYX-dependent proteasome activation that reverses impairment by neurodegenerative-associated oligomers.
Chuah J, Thibaudeau T, Smith D
Commun Biol. 2023; 6(1):725.
PMID: 37452144
PMC: 10349142.
DOI: 10.1038/s42003-023-05082-9.
A Role for the Proteasome Alpha2 Subunit N-Tail in Substrate Processing.
Sahu I, Bajorek M, Tan X, Srividya M, Krutauz D, Reis N
Biomolecules. 2023; 13(3).
PMID: 36979414
PMC: 10046698.
DOI: 10.3390/biom13030480.
Structure of the reduced microsporidian proteasome bound by PI31-like peptides in dormant spores.
Jespersen N, Ehrenbolger K, Winiger R, Svedberg D, Vossbrinck C, Barandun J
Nat Commun. 2022; 13(1):6962.
PMID: 36379934
PMC: 9666519.
DOI: 10.1038/s41467-022-34691-x.
Novel Class of Proteasome Inhibitors: In Silico and In Vitro Evaluation of Diverse Chloro(trifluoromethyl)aziridines.
Ielo L, Patamia V, Citarella A, Efferth T, Shahhamzehei N, Schirmeister T
Int J Mol Sci. 2022; 23(20).
PMID: 36293216
PMC: 9603864.
DOI: 10.3390/ijms232012363.
Bromoditerpenes from the Red Seaweed as Potential Cytotoxic Agents and Proteasome Inhibitors and Related Mechanisms of Action.
Alves C, Silva J, Pinteus S, Guedes R, Guedes R, Alvarino R
Mar Drugs. 2022; 20(10).
PMID: 36286475
PMC: 9604732.
DOI: 10.3390/md20100652.
T-Type Calcium Channels: A Mixed Blessing.
Melgari D, Frosio A, Calamaio S, Marzi G, Pappone C, Rivolta I
Int J Mol Sci. 2022; 23(17).
PMID: 36077291
PMC: 9456242.
DOI: 10.3390/ijms23179894.
Proteasomal subunit depletions differentially affect germline integrity in .
Fernando L, Quesada-Candela C, Murray M, Ugoaru C, Yanowitz J, Allen A
Front Cell Dev Biol. 2022; 10:901320.
PMID: 36060813
PMC: 9428126.
DOI: 10.3389/fcell.2022.901320.
Structural insights into the human PA28-20S proteasome enabled by efficient tagging and purification of endogenous proteins.
Zhao J, Makhija S, Zhou C, Zhang H, Wang Y, Muralidharan M
Proc Natl Acad Sci U S A. 2022; 119(33):e2207200119.
PMID: 35858375
PMC: 9388094.
DOI: 10.1073/pnas.2207200119.
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.
Sellin M, Berg S, Hagen P, Zhang J
Transl Oncol. 2022; 22:101448.
PMID: 35660848
PMC: 9166471.
DOI: 10.1016/j.tranon.2022.101448.